Table 1.
Characteristics of patients with TGCT at the Barretos Cancer Hospital.
| Characteristics | Patients |
|---|---|
| n (%) | |
| TGCT | 97 |
| Age | |
| < 30 years | 49 (50.5%) |
| ≥ 30 years | 48 (49.5%) |
| Histological group | |
| Non-seminoma | 56 (57.7%) |
| Seminoma | 41 (42.3%) |
| Histology | |
| Pure Non-seminoma | 16 (16.5%) |
| Pure Seminoma | 41 (42.3%) |
| Mixed Tumor | 40 (41.2%) |
| Stages (AJCC) | |
| IS | 7 (7.2%) |
| I | 25 (25.8%) |
| II | 27 (27.8%) |
| III | 38 (39.2%) |
| Risk (IGCCCG) | |
| Low (good prognostic) | 38 (39.2%) |
| Intermediate | 15 (15.5%) |
| High (poor prognostic) | 12 (12.4%) |
| N/A | 32 (33.0%) |
| Chemotherapy | |
| PEB | 56 (57.7%) |
| EP | 14 (14.4% |
| TIP | 1 (1.0%) |
| Ignored | 26 (26.8%) |
| Chemosensitivity | |
| Responsive | 62 (63.9%) |
| Refractory | 6 (6.2%) |
| Ignored | 4 (4.1%) |
| N/A | 25 (25.8%) |
AJCC, American Joint Committee on Cancer; IGCCCG, International Germ Cell Cancer Collaborative Group.
N/A, Not applicable.
PEB, Bleomycin, Etoposide and Platinum.
EP, Etoposide and Platinum.
TIP, Paclitaxel, Ifosfamide, and Cisplatin.